Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
BIOJECT MEDICAL TECHNOLOGIES INC (BJCT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/27/2015 |
8-K
| Quarterly results |
| 08/14/2015 |
8-K
| Quarterly results |
| 05/15/2015 |
8-K
| Quarterly results |
| 04/01/2015 |
8-K
| Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Departure of Directors or Certain ...|
Docs:
|
"Note from Company to the Mark A. Logomasini & Associates, Inc. SEP Fund in the principal amount of $116,636",
"Security Agreement dated March 3, 2015, by and among the Company, Bioject Inc. and Mark A. Logomasini & Associates, Inc. SEP Fund",
"Note from the Company to John E. Anderson in the principal sum of $50,000",
"Note from the Company to Sam Bhattacharjee in the principal sum of $50,000",
"Note from the Company to Sam Bhattacharjee in the principal sum of $50,000",
"Note from the Company to Life Sciences Opportunities Fund II, LP in the principal sum of $45,552",
"Note from the Company to Life Sciences Opportunities Fund (Institutional) II. LP in the principal sum of $254,448",
"Security Agreement dated February 18, 2015, by and among the Company, Bioject Inc., Life Sciences Opportunities Fund II, LP and Life Sciences Opportunities Fund (Institutional) II, LP",
"BIOJECT REPORTS UNAUDITED YEAR-END AND FOURTH QUARTER 2014 FINANCIAL RESULTS Tigard, OR - March 25, 2015 - Bioject Medical Technologies Inc. , a developer and manufacturer of needle-free injection therapy systems, today reported unaudited financial results for the year and quarter ended December 31, 2014. The financial results are unaudited and actual results may vary. 12 Months Ended December 31, 2014" |
|
| 11/12/2014 |
8-K
| Quarterly results |
| 08/15/2014 |
8-K
| Quarterly results|
Docs:
|
"Form of Note from Bioject to the Mark A. Logomasini & Associates, Inc. SEP Fund in the principal amount of $100,000",
"For value received,",
"SECURITY AGREEMENT This Security Agreement is made June 25, 2014 by and among Bioject Medical Technologies Inc. and its wholly owned subsidiary Bioject Inc. , each an Oregon corporation, and each with offices at, 7180 SW Sandburg Street, Tigard, Oregon 97223 , and Mark A. Logomasini & Associates, Inc. SEP Fund and Amir Ness, the holders of the Company's Senior Secured Bridge Promissory Notes in the amounts of $100,000 and $50,000, respectively, dated June 23, 2014 and June 25, 2014, respectively and with the addresses set forth on the signature page hereto . RECITALS The Noteholders have agreed to make a secured loan to the Company, evidenced by the Notes, are secured by all the accounts receivable from Ferring Pharmaceuticals to the Company, whether presently existing or hereafter acquire...",
"BIOJECT REPORTS UNAUDITED SECOND QUARTER 2014 FINANCIAL RESULTS" |
|
| 07/03/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/15/2014 |
8-K
| Quarterly results |
| 05/06/2014 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/20/2014 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits |
| 10/01/2013 |
8-K
| Quarterly results |
| 08/30/2013 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 07/17/2013 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 02/20/2013 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"LOGOMASINI EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement is dated February 15, 2013 between: BIOJECT MEDICAL TECHNOLOGIES INC. , a corporation incorporated under the laws of the State of Oregon having its principal offices at 7180 SW Sandburg Street, Suite 100, Tigard, OR 97223 BIOJECT INC . , a corporation incorporated under the laws of the State of Oregon having its principal offices at 7180 SW Sandburg Street, Suite 100, Tigard, OR 97223 AND: Mark Logomasini, having an office address at 26212 Dimension Drive, Suite 260, Lake Forest, CA 92630 . RECITALS WHEREAS, the Executive has heretofore been employed by the Company. WHEREAS, the Company and Executive desire to set forth in this agreement the terms and conditions of Executive's employment with the Company. NOW, TH..." |
|
| 04/03/2012 |
8-K
| Form 8-K - Current report |
| 11/08/2011 |
8-K
| Form 8-K - Current report |
| 08/30/2011 |
8-K
| Form 8-K - Current report |
| 08/10/2011 |
8-K
| Quarterly results|
Docs:
|
"BIOJECT REPORTS SECOND QUARTER 2011 FINANCIAL RESULTS Revenue Doubles Over Second Quarter 2010 PORTLAND, OR, August 10, 2011 - Bioject Medical Technologies Inc. , a leading developer of needle-free drug delivery systems, today reported financial results for the second quarter ended June 30, 2011. Bioject reported revenues of $2.4 million for the quarter ended June 30, 2011, compared to revenues of $1.2 million in the comparable 2010 period. Product sales were $2.2 million in the 2011 period compared to $1.0 million in the comparable 2010 period. License and technology fees were $209,000 for the quarter ended June 30, 2011, compared to $117,000 in the comparable 2010 period. The Company reported operating income of $276,000 in the second quarter of 2011 compared to an operating loss of $593..." |
|
| 07/01/2011 |
8-K
| Form 8-K - Current report |
| 06/14/2011 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/11/2011 |
8-K
| Quarterly results|
Docs:
|
"BIOJECT REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS Revenues increase 47% over first quarter 2010 PORTLAND, OR - May 11, 2011 - Bioject Medical Technologies Inc. , a leading developer of needle-free drug delivery systems, today reported financial results for the quarter ended March 31, 2011. For the quarter ended March 31, 2011, Bioject reported revenues of $1.7 million compared to $1.2 million in the comparable year-ago quarter. Product sales for the first quarter of 2011 were $1.6 million compared to $1.1 million in the year-ago quarter. License and technology fees for the first quarter of 2011 were $122,000, compared to $96,000 in the comparable year ago period. Operating expenses for the first quarter of 2011 were $1.9 million compared to $1.7 million in the first quarter of 2010. The..." |
|
| 03/31/2011 |
8-K
| Form 8-K - Current report |
| 03/23/2011 |
8-K
| Form 8-K - Current report |
| 11/10/2010 |
8-K
| Form 8-K - Current report |
| 08/04/2010 |
8-K
| Form 8-K - Current report |
| 06/15/2010 |
8-K
| Form 8-K - Current report |
| 03/17/2010 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits|
Docs:
|
"BIOJECT REPORTS DECEMBER 31, 2009 RESULTS Operating loss and net loss allocable to common shareholders decrease 65% compared to fiscal 2008 PORTLAND, OR - March 17, 2010 - Bioject Medical Technologies Inc. , an innovative developer and manufacturer of needle-free injection therapy systems, today reported financial results for the year and quarter ended December 31, 2009. For the year ended December 31, 2009, Bioject reported revenues of $6.7 million compared to revenues of $6.5 million in 2008. Product sales were $6.1 million in 2009 compared to $5.8 million in 2008. License and technology fees for 2009 were $599,000 compared to $667,000 in 2008. The Company reported an operating loss of $884,000 and net loss allocable to common shareholders of $1.1 million for 2009, compared to an operati..." |
|
| 01/14/2010 |
8-K
| Form 8-K - Current report |
| 12/21/2009 |
8-K
| Appointed a new director|
Docs:
|
"Articles of Amendment to 2002 Restated Articles of Incorporation",
"Series G Convertible Preferred Stock Purchase Agreement between Bioject Medical Technologies Inc. Life Sciences Opportunities Fund II, L.P., Life Sciences Opportunities Fund (Institutional) II, L.P., and Edward Flynn",
"Registration Rights Agreement between Bioject Medical Technologies, Inc., Life Sciences Opportunities Fund II, L.P., Life Sciences Opportunities Fund (Institutional) II, L.P., Edward Flynn, Ralph Makar, David Tierney, Richard Stout, Christine Farrell, and the Investors listed on Exhibit A thereto",
"BIOJECT CLOSES PREVIOUSLY ANNOUNCED EQUITY FINANCING Completion of Series G Preferred Financing Converts Portion of Debt and Provides Cash PORTLAND, OR, December 21, 2009 - Bioject Medical Technologies Inc. , a leading developer of needle-free injection therapy systems, today announced that on December 18, 2009, it completed a Series G Preferred Stock financing with each of Life Sciences Opportunities Fund II, L.P., Life Sciences Opportunities Fund II, L.P. , and Edward Flynn for the purchase of an aggregate of 92,448 shares of its Series G Convertible Preferred Stock at a price of $13.00 per share. Gross proceeds from the sale were $1,201,834, payable by payment of $500,000 in cash and the cancellation of the $600,000 outstanding principal amount of and $101,834 accrued interest through D..." |
|
| 11/05/2009 |
8-K
| Form 8-K - Current report |
| 09/17/2009 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 09/01/2009 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 08/18/2009 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 08/13/2009 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|